Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 11 Lung Neoplasms 3 Brain Neoplasms 2 ALK-positive Advanced NSCLC 2 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasm Metastasis 1 NSCLC 1 Meningioma 1 Lymphoma, Large-Cell, Anaplastic 1 Gastrointestinal Neoplasms 1 Ependymoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma 1 Breast Neoplasms 1

Interventions

Bevacizumab 10 Magnetic Resonance Spectroscopy 9 Temozolomide 8 Cyclophosphamide 8 Etoposide 7 X-Rays 6 Phantoms, Imaging 6 Specimen Handling 5 Nuclear Medicine Department, Hospital 5 Cisplatin 5 Radiotherapy 4 Irinotecan 4 Filgrastim 4 Carboplatin 4 Biopsy 4 Erlotinib Hydrochloride 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 sargramostim 2 palbociclib 2 olaparib 2 larotrectinib 2 ivosidenib 2 etoposide phosphate 2 erdafitinib 2 ensartinib 2 Vincristine 2 Vemurafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ependymoma × brigatinib × Clear all

NCT04374305 2026-05-06

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡